News for Amryt Pharma plc (AMYT.L)

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

Rising frequency of uncommon illnesses and increasing number of governments providing regulatory incentives for development of orphan drugs are major...

The global market for orphan drugs is witnessing a surge in demand due to various factors, together with an increase in the prevalence of rare disorders,...

/PRNewswire/ -- The

GuruFocus Article or News written by GuruFocus Research and the topic is about:

GuruFocus Article or News written by GuruFocus Research and the topic is about:

Chiesi Group announces mid-year turnover of €1,497 million Substantial growth of each of Chiesi’s business areas Europe remains the biggest market, followed by…

I-Mab has appointed Raj Kannan as its new CEO, filling its top position 18 months after its last top executive quit.

Bruce & Co. BRUFX portfolio, holdings, 13f and stock news. Updated: 2023-02-15 portfolio, holdings, 13F and news. Updated: 2023-02-15

Amryt Pharma is being acquired at $14.50 per share and a contingent value right and is trading at $14.69. Find out why AMYT stock is a Buy.

GuruFocus Article or News written by insider and the topic is about:

Bruce & Co. BRUFX portfolio, holdings, 13f and stock news. Updated: 2022-11-15 portfolio, holdings, 13F and news. Updated: 2022-11-15

NEW YORK, Jan. 15, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

GuruFocus Article or News written by insider and the topic is about:

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

NEW YORK, July 8, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have